Here’s what you need to know.
1. Jecure is a biotech company with a proprietary liver disease platform. To date, it has developed treatment programs for non-alcoholic steatohepatitis and fibrosis.
2. Versant committed $20 million to Jecure and was the sole investor in a series A funding round.
3. Jecure CEO Jeffrey Stafford, PhD, and James Veal, PhD, founded Jecure and were senior managers at a cancer company which Versant founded.
4. Dr. Stafford said, “The series A backing of Jecure renews a successful partnership with Versant, and provides us the opportunity to build another transformational company in a field that is starving for innovation. We continue to have ongoing discussions with strategic and financial partners while we independently build a pipeline of drug candidates based on the discoveries from the UCSD NASH platform.”
More articles on gastroenterology:
4 GI devices receive FDA clearance in January 2017
GI leader to know: Dr. David Freeto of Queen of the Valley Medical Center
ArQule’s, Daiichi Sankyo’s hepatocellular carcinoma drug fails to improve survival in HCC patients
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.